scholarly journals A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly

2003 ◽  
Vol 348 (7) ◽  
pp. 583-592 ◽  
Author(s):  
Lindon M.H. Wing ◽  
Christopher M. Reid ◽  
Philip Ryan ◽  
Lawrence J. Beilin ◽  
Mark A. Brown ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
The Elderly ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

scholarly journals The Treatment of Angiotensin-converting Enzyme Inhibitors in Coronavirus Disease 2019 Patients with Hypertension: A Narrative Review

2021 ◽  
Vol 9 (F) ◽  
pp. 389-394
Author(s):  
Mohammad Rudiansyah ◽  
Haryati Haryati ◽  
Enita Rakhmawati Kurniaatmaja ◽  
Nanik Tri Wulandari ◽  
Lily Runtuwene ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Clinical Symptoms ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
The Elderly ◽  
World Health ◽  
Respiratory Disorder ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

A new strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces coronavirus disease 2019 (COVID-19), a contagious respiratory disorder resulting in illness. Meanwhile, the World Health Organization classified this virus as a pandemic due to its rapid transmission and daily growing fatality rates. The condition is commonly manifested as clinical symptoms such as fever, cough, shortness of breath, and cardiovascular disease. Although there is a high probability of COVID-19 patients developing cardiovascular problems, such as hypertension, there is no established causative association between both conditions. In general, this type of comorbidity is extremely common in the elderly, which increases their risk of infection with the SARS-CoV-2 virus. The International Society of Hypertension issued the most recent guidelines for the treatment and management of hypertension in 2020, of which the most employed are angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARB). Therefore, this research aims to investigate the treatment of ACE-i/ARB in hypertensive individuals with COVID-19. The reason is that there have been some concerns expressed about the usage of these medications due to their influence on angiotensin-converting enzyme 2 (ACE2), which is the entrance site for SARS-CoV-2, particularly in the lungs. Subsequently, the results showed that discontinuing ACE-i/ARB is not advised, especially during the pandemic. This is based on data comparing mortality rates between participants on ACE-i/ARB and those not on ACE-i/ARB using cases and guidelines for managing hypertension during the pandemic.

Sign in / Sign up

Export Citation Format

Share Document